To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

Syndax (SNDX) delivered earnings and revenue surprises of 13.27% and 96.85%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX ), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported ...

Syndax (SNDX) expects that its cash, cash equivalents and marketable securities, together with the $350M from the sale of a portion of the Niktimvo royalty and anticipated product revenue and interest ...

Syndax Pharmaceuticals has entered a synthetic royalty funding agreement with Royalty Pharma, focused on US net sales of Niktimvo (axatilimab-csfr), a treatment for chronic graft-versus-host disease ...

WALTHAM, Mass., Nov. 5, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that multiple abstracts evaluating revumenib, an oral small molecule menin inhibitor, have been ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax ...

Analysts are estimating that Syndax Pharmaceuticals will report an earnings per share (EPS) of $-1.11. Investors in Syndax Pharmaceuticals are eagerly awaiting the company's announcement, hoping for ...

On Friday, Syndax Pharmaceuticals Inc (SNDX) stock saw a modest uptick, ending the day at $18.98 which represents a slight increase of $0.12 or 0.64% from the prior close of $18.86. The stock opened ...

Fintel reports that on October 24, 2024, UBS initiated coverage of Syndax Pharmaceuticals (NasdaqGS:SNDX) with a Buy ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Syndax Pharmaceuticals Inc. (SNDX) on Tuesday reported a loss of $84.1 million in its third quarter. The Waltham, Massachusetts-based company said it had a ...

Jefferies has recently initiated Syndax Pharmaceuticals Inc (SNDX) stock to Buy rating, as announced on June 28, 2024, according to Finviz. Earlier, on January 31, 2024, Scotiabank had reduced the ...